08:01 AM EDT, 08/05/2025 (MT Newswires) -- Knight Therapeutics ( KHTRF ) on Tuesday said it submitted a marketing authorization application for Crexont to the Mexican health regulatory agency for the treatment of Parkinson's disease.

The company applied to Health Canada to approve the same medicine last week.

Knight had sealed an agreement with Anmeal Pharmaceuticals last year to commercialize Crexont in Canada and Latin America.

This comes after Knight over the Canada holiday weekend said it has expanded its relationship with Incyte to distribute retifanlimab and axatilimab in Latin America.

Incyte will be responsible for the manufacturing and supply of the two drugs and Knight will seek regulatory approvals and distributing both medicines in Latin America, a statement said.

Retifanlimab is approved in the U.S. and Europe for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC), a rare and aggressive type of skin cancer.

Axatilimab received FDA approval last year for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and certain pediatric patients. Chronic GVHD is a complication of allogeneic stem cell transplantation in which the donor's immune cells attack the recipient's tissues.

"We are thrilled to expand our partnership with Incyte and for the opportunity to bring two innovative biologic products to the LATAM region," said Samira Sakhia, chief executive officer of Knight Therapeutics ( KHTRF ). "These therapies are highly complementary to our existing portfolio and will significantly strengthen our presence in oncology and hematology, reinforcing our commitment to delivering transformative treatments to patients across Latin America."